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Stenting the arterial duct: Practical 
aspects and review of outcomes
Maintaining ductus arteriosus patency by the percutaneous place-
ment of coronary artery stents provides an alternative to surgical 
systemic-to-pulmonary artery shunts. This maintains pulmonary 
blood flow and serves as a temporary bridge towards later surgical 
repair. Since the first report by Gibbs, et al. in 1992, the success and 
outcome of ductal stenting have improved due to advances in 
technique and equipment. This is now considered an acceptable 
option for these patients in many centres.
OUTCOMES OF DUCTUS ARTERIOSUS 
STENTING: A REVIEW OF CURRENT 
LITERATURE 
Immediate outcomes of PDA stenting
A detailed description of the immediate outcomes of PDA 
stenting can be viewed in Table 1.(3-15) The majority of patients 
underwent patent ductus arteriosus (PDA) stenting at an early age, 
usually shortly after birth, with weights ranging between 1.5 - 4.5kg. 
Procedural success was good and stent placement was successful 
in 80 to 100% of the cases. The effectiveness of the procedure is 
highlighted by the fact that all studies have shown a significant 
improvement in arterial saturations after stent placement. Some 
cases have required more than 1 stent in an attempt to ensure 
adequate coverage of the entire ductal length. Reported peri-
procedural complication rates were low: major complications 
included stent migration, acute thrombosis and permanent femoral 
vessel damage. Very few immediate deaths were directly related to 
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PDA STENTING
INTRODUCTION
Cyanotic congenital heart disease with duct-dependent pulmonary 
blood flow is a life threatening condition. Typical lesions include 
pulmonary and tricuspid atresia, critical pulmonary stenosis and 
tetralogy of Fallot. Establishing adequate pulmonary blood flow is 
essential for survival in these patients and early intervention is often 
required. 
This may be accomplished by using intravenous prostaglandin 
therapy to maintain duct patency until surgical intervention is 
possible (palliation or complete repair). Surgical options may, how-
ever, be limited by centre experience and patient factors such as 
critical illness and very low birth weight. Surgical palliation consists 
of a systemic-to-pulmonary artery shunt as a first stage procedure. 
Although this has been used since the mid 1940s, it is still asso-
ciated with significant morbidity and mortality.(1,2) Complications 
such as shunt thrombosis, pleural fluid collections and nerve injury 
with diaphragmatic paralysis have been described.(3,4) Ongoing 
problems include progressive endovascular growth with obstruc-
tion, distortion and differential growth of the branch pulmonary 
arteries, as well as adhesions which may complicate future surgeries.
Cyanotic congenital heart lesions with duct-dependent 
pulmonary blood fl ow often require early intervention. 
Surgical palliation remains the treatment of choice, but is 
associated with substantial morbidity and mortality. Ductal 
stent implantation is becoming a recognised alternative to 
maintain pulmonary blood fl ow. Results of ductal stenting 
have improved and outcomes are good. We discuss the 
outcomes of published data and the practical aspects of 
ductal stenting.  SAHeart 2013;10:514-519
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the procedure and were reported in only 2 studies: acute stent 
thrombosis (n=1),(14) pulmonary haemorrhage (n=1) and retro-
peritoneal haemorrhage secondary to an underlying coagulopathy 
(n=1).(15) Early re-intervention within the same admission consisted 
of mostly duct re-stenting. In most cases this was necessary to 
overcome early significant constriction as a result of unstented 
ductal segments. Deaths before discharge (not including deaths 
related to the procedure) were few and unrelated to stent 
implantation. These were mostly due to nosocomial sepsis and 
respiratory complications.
Mid-to-long term outcomes of PDA stenting 
The majority of studies followed up on patients at 6 months post-
procedure. Follow-up intervals were scheduled to detect stent 
occlusion. A summary of the mid-to-long term outcomes of PDA 
stenting can be seen in Table 2.(3-15) Progressive stent stenosis 
TABLE 1:  Immediate outcomes of PDA stenting
*See text for details
 Number of cases    
Major complications
  
Deaths
 
References
 
 attempted  Age at Weight (kg)  Early 
before (reported  stent at stent  reintervention 
discharge* success %) 
 21 (100) median 13.3d median 3.06 2 (permanent vascular occlusion) 2 (restent) 2 Schneider 1998(6)
 10 (100) median 6d median 3.3  1 (restent) 1 Gewillig 2004(7)
 21 (95.2) median 10.5d median 3.3 3 (stent migration), 2 (stent thrombosis) 3 (restent) 2 Michel-Behnke 2004(8)
 56 (91) median 2.3mo median 3.9 1 (stent migration), 1 (hour-glass stent)  2 Alwi 2004(3)
 10 (100) median 16d median 2.7    Mahesh 2005(9)
 10 (80) median 3.5mo median 5.4    Celebi 2007(10)
 16 (87.5) mean 24d mean 2.9 2 (stent migration) 4 (restent) 1 Hussain 2008(11)
 26 (92.3) mean 15.2d mean 3.3    Santoro 2008(5)
 27 (100) median 6d median 3.2 1 (stent migration) 2 (dilatation), 1 (restent)  Schranz 2010(12)
 45 (93.3) mean 66d mean 4.4    Erdem 2011(13)
 33 (100) range 3 - 56d range 2.7 - 4.1 1 (stent migration) 2 (dilatation) 2 Matter 2012(4)
 18 (83.3) median 20d median 3.2 1 (stent thrombosis), 1 (duct spasm)  2 Amoozgar 2012(14)
 13 (100) mean 10.5d mean 3.1    Odemis 2012(15)
TABLE 2:  Mid-to-long term outcomes of PDA stenting
 
Number
 
Age at
 Cases of  
Palliative
  
Complete
   
 
followed up
  
follow-up
 stent 
surgery
 
surgical repair
 Deaths References
    stenosis   
 19 group 1 median 8.7mo,   4 (dilated), 7 (to surgery)  7  Schneider 1998(6)
  group 2 median 6mo
 10 median 5.7mo 1 (restent) 2 2  Gewillig 2004(7)
 21 mean 975d 6 (dilated) 8 4  Michel-Behnke 2004(8)
 49 mean 9.6mo 4 (to surgery), 2 (restent),  4  1 Alwi 2004(3)
   3 (dilated)
 10 median 5.5mo 1 (dilated)    Mahesh 2005(9)
 8 mean 9.3mo 1 (restent)    Celebi 2007(10)
 13 mean 13mo 1 (dilated), 4 (restent) 6 2 1 Hussain 2008(11)
 24 mean 15mo 2 (to surgery), 4 (dilated/restent) 2 7  Santoro 2008(5)
 27   18 6 2 Schranz 2010(12)
 42 mean 34.5mo 12 (dilated) 20 14 2 Erdem 2011(13)
 33 3  24  4 Matter 2012(4)
 15 6mo    3 Amoozgar 2012(14)
 13  1 (to surgery) 5  2 Odemis 2012(15)
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was reported in a few cases. These cases were either re-stented or 
a balloon angioplasty was performed. Where this was not successful 
in improving systemic saturations, surgery was carried out. Spon-
taneous occlusion of the stented duct without a decrease in arterial 
saturations has been reported at follow-up in lesions with an 
additional source of pulmonary blood flow. Lesions showing this 
phenomenon included critical pulmonary stenosis where the right 
ventricle had adapted and adequately increased in size to support 
pulmonary blood flow. 
A small number of deaths were reported at follow-up and occurred 
between the time of initial discharge and before the first surgery 
was performed. These were mainly attributed to sepsis and 
pneumonia in most cases and unrelated to the PDA stent. 
At first surgery (including systemic-to-pulmonary artery shunts, 
cavopulmonary shunts and complete repair), reported pulmonary 
artery growth was reasonable in all studies. The effect of PDA 
stenting on the anatomy of the branch pulmonary arteries is still 
unclear. Early on a significant number of cases required pulmonary 
arterioplasty. Lately most studies reporting on complications at 
first surgery found that most stents were easily removed with very 
few patients requiring reconstruction for pulmonary artery distor-
tion. As a matter of fact, it seems that pulmonary artery growth is 
promoted by PDA stenting. It has been postulated that since a 
stent is implanted in the natural position of a duct, this may result in 
a better angle between the PDA and the branch pulmonary arteries, 
allowing for improved growth.(5)
TECHNICAL ASPECTS
The procedure is usually performed under general anaesthesia or 
deep conscious sedation. In our practice, all patients are discussed 
beforehand with the cardiothoracic team and surgical standby is 
routinely available. In order to facilitate stent placement, it is 
preferable to have a mildly constricted duct (enough to allow the 
stent to be secured). It is therefore recommended to stop 
prostaglandin infusion 6 - 12 hours before the procedure. However, 
in patients with low oxygen saturations, intravenous prostaglandin 
administration should be continued, but titrated down to the 
lowest dose required to maintain ductal patency. Prolonged 
prostaglandin treatment may give rise to a big, dilated ductus, which 
usually precludes stent placement due to the lack of a narrowed 
ductal segment where the stent can find adequate "grip". If there 
are any concerns regarding PDA size, it is advisable to confirm 
ductal size in the neonatal unit using echocardiography before 
transport to the catheterisation laboratory and to delay the 
procedure if the duct does not show a degree of constriction. It is 
imperative to have intravenous prostaglandin and Ibuprofen (cyclo-
oxygenase inhibitor) available in the catheterisation laboratory. 
If ductal diameter is large as a result of prostaglandin therapy it 
may be of benefit to administer a prostaglandin inhibitor (ibuprofen 
5 - 10mg/kg intravenously) in theatre and then to continue with 
stent placement once constriction occurs. We prefer to ensure 
good guide wire position before administering a prostaglandin 
inhibitor as a protective measure. Also, all equipment should be 
ready in case immediate intervention is required. 
Retrograde femoral arterial access is most commonly used but 
carotid and axillary routes have been described. The latter requires 
cut down by a vascular surgeon. Depending on the underlying 
pathology, antegrade stenting through a stenotic pulmonary valve 
may occasionally be possible. Smaller sheath sizes are preferred to 
avoid vascular complications and we prefer starting with a short 4 
PDA STENTING
FIGURE 1:  PDA pre stent implantation
The asterisk indicates a PDA considered for stent placement. This 
ductus demonstrates mild convolution and is fairly straight with a 
good anchoring point for a stent at the stenotic pulmonary aspect. 
Arrow shows origin of the left pulmonary artery.
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French (F) sheath. Care should be taken in low birth weight infants, 
as femoral vessel injury is an ever-present reality. Patients are 
heparinised (50 - 100U/kg ivi) and routine prophylactic antibiotics 
are given according to local protocols. 
Meticulous investigation to delineate ductal anatomy is essential 
and initial angiography is usually performed in the antero-posterior 
and lateral positions. Right anterior oblique projections with some 
caudal angulation may be of benefit if uncertainty exists regarding 
underlying PDA morphology and/or branch pulmonary artery 
anatomy. Some experimentation is typically required to find the 
best angulation to view the anatomy. The following should be 
clearly demonstrated: origin from the aortic arch, diameter at 
pulmonary artery (most often the narrowest), ampulla diameter 
and ductal length (Figure 1). Ductal length can be misleading due to 
the fact that ducts are often convoluted or angled and thus difficult 
to measure accurately. Therefore, it is recommended to measure 
the length of the PDA only after it has been crossed and with the 
guide wire in position; this tends to straighten the ductus and allows 
an improved estimation of ductal length.
Various catheters may be utilised for angiography and stent. Routine 
angiography is usually performed with a pigtail catheter followed by 
selective and detailed angiography. We prefer to do angiograms in 
close approximation to the ductal origin and use an array of 
catheters for example: right Judkins, Cobra, Multipurpose (Cordis, 
Roden, Netherlands). In the majority of cases, the configuration of 
a right coronary artery catheter should enable one to cross the 
duct safely, but sometimes a cut-off pigtail may be useful to cross 
the PDA. In difficult cases a coaxial system may be extremely 
helpful.(16) In our experience, the ductal tissue in some of these 
PDAs may be quite sensitive and prone to spasm. We therefore 
routinely use a microcatheter with a very soft guide wire e.g. 
Progreat™ (Terumo, Somerset, NJ, US) to cross the duct. Once 
the duct has been crossed, the microcatheter is positioned as 
distally as possible in one of the pulmonary artery branches. This 
allows one to safely and easily exchange the soft guide wire with a 
stiffer 0.014” wire. Care should be taken to obtain stable guide 
wire position since this will allow one the best opportunity for 
successful stent placement. In our practice the most common 
coronary guide wires (0.014”) used includes the Galeo (Biotronik, 
Berlin, Germany) and the ChoICETMPT (Boston Scientific, Miami, 
USA) which lend various degrees of support depending on 
required wire stiffness. As a general rule - the more complex and 
difficult to cross, the stiffer the guide wire that should be used. It is 
also helpful to have an extendable guide wire available since some 
microcatheters are quite long and standard length guide wires may 
thus be too short to enable removal of the microcatheter without 
losing guide wire position. 
Standard bare metal coronary stents commonly available in adult 
interventional catheterisation laboratories are used e.g. Omega™, 
(Boston Scientific, Natick, MA, US) or Racer® (Medtronic, 
Minneapolis, MN, US) (Figure 2). As it happens, one often has to 
use whatever is available, but stents with the lowest profile are 
preferred. Open cell designs may be advantageous in a convoluted 
duct. Drug-eluting stents should be avoided and are not approved 
for use in children. It should be pointed out that this is an off-
label indication for a coronary stent. It is of the utmost importance 
to stent the entire length of the duct as any unstented segment 
will soon become constricted and may be extremely difficult to 
recannulate (Figure 3). Stent foreshortening may be variable and 
should be taken into account when deciding on the length of 
stent. Manufacturers supply a chart indicating expected final stent 
length at different diameters. We usually select a stent 1 - 2mm 
longer than the ductus after taking these facts into account. 
FIGURE 2:  Stented PDA
Successful stent placement in arterial duct. Note good guide wire 
position. Stent was delivered by means of  5F Vistabritetip®  catheter 
(for more details see text).
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Some stent protrusion into the aorta and pulmonary artery 
(1 - 2mm) is acceptable. We keep to the stent sizes as recom-
mended by Alwi(3) : 3.5 mm diameter in those patients weighing 
<3kg, 4mm in those weighing 3 - 5kg, and 4.5mm stents in 
those patients weighing 5kg and above. 
If patients are ventilated, they should be extubated as early as 
possible. Heparin infusion is continued at a dose of 25U/kg/hr for 
24 - 48 hours. Aspirin is simultaneously initiated at 2 - 3mg/kg/day 
and patients are discharged on this dose.
GENERAL COMMENTS
As we gained experience with the technique, we now deliver stents 
bare without using a guiding catheter/long sheath especially in 
smaller infants. Control angiography can be performed through the 
side port of the 4F sheath with a saline chaser. However, in more 
difficult cases or in a situation where sharp angles need to be 
traversed, a Vistabritetip® (Cordis, Florida, US) catheter is used 
to deliver the stent – this lends additional support whilst simulta-
neously allowing control angiography. Filling a nasogastric tube with 
a small volume of diluted contrast agent may serve as a good 
marker (especially aortic origin of the PDA) to facilitate stent 
placement.
In our catheterisation laboratory, we avoid stenting tortuous and 
vertical ducts. If ductal spasm occurs, we immediately start with a 
continuous infusion of intravenous prostaglandin. If the PDA was 
crossed with a guide wire, it is imperative to leave it in position as 
it tends to “splint” the duct open and also allows one to do 
emergency stenting if required.
Although rare, acute stent thrombosis may occur. In order to 
avoid it, one should aim to limit the time spent by the guide wire 
across the ductus to less than 10 - 15 minutes. Should thrombosis 
occur, it is imperative to maintain guide wire position and a local 
infusion of streptokinase or alteplase may be considered. In cases 
of overshunting, due to a large internal diameter of a stented 
ductus, medical treatment with diuretics is preferred. Alternatively, 
the inner diameter of the stent may be decreased by means of 
placing an additional stent or stents, or a covered stent inside the 
original stent. Additional technical details can be found in the 
bibliography.(3,7,8)
LIMITATIONS OF PDA STENTING
The most frequently reported limitations include technical problems 
related to patient size (e.g. prematurity) and duct morphology. 
Numerous variations of PDA anatomy have been described and 
may affect the success of stent delivery. Lesions with a higher 
success rate include pulmonary atresia with ventricular septal 
defect (VSD) and tricuspid atresia as these are associated with a 
simpler duct anatomy. Pulmonary atresia with intact ventricular 
septum is often associated with long, tortuous ducts with multiple 
areas of stenoses.(4) Therefore, complicated duct anatomy is a 
contraindication to stent placement.(11) Branch pulmonary artery 
stenosis is aggravated by PDA stenting and this should therefore 
also be avoided.(3) Other reported peri-procedural complications 
include acute stent thrombosis (2 - 3%), pre-stent ductal spasm 
(<1%), stent dislodgement and migration, vessel or chamber 
perforation and neointimal proliferation of which the overall inci-
dence is low.(3,8,11,12,14) Long term complications resemble those of 
surgical shunts and consist of progressive stent stenosis, pulmonary 
overflow with pulmonary hypertension and branch pulmonary 
artery distortion.(3)
PDA STENTING
FIGURE 3:  Result of an incomplete ductal stent placement
The short arrow points towards a stenotic ductal segment resulting 
from incomplete ductal covering becoming apparent 7 days after initial 
stent placement. Note the acute angle and extreme stenosis of the 
remaining ductal tissue at the aortic origin of the PDA. This was 
eventually crossed using a cut-off pigtail catheter and a co-axial 
system. Longer arrow demonstrates a contrast filled nasogastric tube 
used as a marker for stent delivery. Asterisk shows patent original 
stent in situ.
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ADVANTAGES OF PDA STENTING 
COMPARED TO SURGERY
A major benefit of PDA stenting is a reduced waiting period before 
intervention; this may be especially helpful in centres with crowded 
surgical lists. This also avoids the side-effects of continuous pro-
staglandin infusion. Recovery time post-procedure is rapid and 
hospital stay is short. It is a minimally invasive procedure with a 
low risk profile and can be performed on relatively small and 
premature newborns that are often critically ill. 
CONCLUSION
Early reparative surgery should be considered the treatment of 
choice for the majority of cyanotic cardiac conditions. In cases 
where this is not possible, the modified Blalock Taussig shunt 
should be considered as the gold standard of treatment and all 
other therapies should be measured against it.
Stenting of the arterial duct offers an alternative to surgical systemic 
to pulmonary artery shunts. Current literature provides evidence 
that ductal stenting is feasible, safe and effective. Results are 
encouraging and the technique is now well established. 
The procedure should, however, be carried out by skilled operators 
in a unit accustomed to dealing with children. It should be empha-
sised that the whole length of the duct should be covered by the 
stent. 
PDA stenting is a viable option in selected cases. In developing 
countries this interventional catheter procedure may assist to 
reduce the load on overburdened surgical lists.
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